GLP 1 Medicaid coverage narrows as heart and kidney evidence grows
A Pharmacy Times review says 13 state Medicaid programs covered GLP 1 drugs for obesity in January 2026, down from 16, while Medicare relies on a temporary Bridge through 2027. Heart and kidney benefits stay tied to specific drugs and trials.
What's new
A Pharmacy Times review published Nov. 6 says Medicaid coverage of GLP 1 drugs for obesity has narrowed to 13 states while heart and kidney trial evidence grows. Medicare coverage runs through a temporary Bridge to the end of 2027 after CMS delayed the Part D portion of its BALANCE Model.
Why it matters
Medicaid obesity coverage is optional for states, so budget decisions decide access for low income patients. Heart and kidney benefits are shown for specific drugs and populations, not the whole class.
What's next
Watch state budget decisions on Medicaid coverage, which states join the Medicaid side of BALANCE, and any CMS action on Part D before the Medicare GLP 1 Bridge ends on December 31, 2027.
WASHINGTON. GLP 1 Medicaid coverage for obesity is narrowing while the trial record for heart and kidney benefits keeps growing, a clinical review in Pharmacy Times said on Nov. 6. The review counts 13 state Medicaid programs that covered the drugs for obesity in January 2026, down from 16 in October 2025. It also notes that federal plans to widen access have slipped. Medicare will rely on a temporary demonstration through 2027 after a broader price model stalled in Part D. The review summarizes published work and reports no new data.
Heart and kidney trials back specific drugs only
Several cardiovascular outcomes trials have reported fewer major adverse cardiovascular events, or MACE, with individual GLP 1 drugs, the Pharmacy Times review says. It lists liraglutide, semaglutide, dulaglutide, albiglutide and efpeglenatide. Albiglutide is no longer sold, and efpeglenatide remains an experimental drug without FDA approval. Benefits were larger for some products and study groups than for others, according to the review. The SELECT trial, published in the New England Journal of Medicine in 2023, found that once weekly semaglutide lowered MACE risk in people with overweight or obesity and established cardiovascular disease. None of those participants had diabetes. It is the only trial the review cites for heart outcomes in people without diabetes.
Kidney outcomes are drawing more attention. Earlier trials pointed to possible effects on albuminuria, which means protein leaking into the urine. The FLOW trial, reported in 2024 and built to test kidney effects directly, enrolled adults who had both chronic kidney disease and type 2 diabetes, and semaglutide cut their chance of reaching a combined kidney end point, the review reports. Oral candidates are now being tested on the same question, as our report on elecoglipron kidney data shows. The review warns against stretching these results to every GLP 1 drug or every patient group. Any claim of heart or kidney protection, it argues, needs to name one product, one population and one end point, and point to the trial that measured it. The review does not pool results or estimate a class effect.
Medicaid obesity coverage falls as state budgets tighten
GLP 1 Medicaid coverage is a state choice when obesity is the diagnosis, according to KFF, though programs must pay for the drugs in diabetes, cardiovascular disease and sleep apnea. Its January 2026 analysis found 13 state Medicaid programs covering the drugs for obesity under fee-for-service, against 16 in its October 2025 budget survey. KFF said California, New Hampshire, Pennsylvania and South Carolina ended obesity coverage in that window. North Carolina dropped coverage in October 2025 during a legislative budget standoff and restored it in December, KFF said. Where coverage exists, the drugs usually carry prior authorization or other use controls. The KFF Medicaid analysis said the cuts likely reflected state budget strain and the high cost of covering these drugs.
Its January 2026 analysis found 13 state Medicaid programs covering the drugs for obesity under fee-for-service, against 16 in its October 2025 budget survey.
The decline may not have stopped. Pharmacy Times, citing an April 2026 Stateline report, said more states have weighed ending coverage as their budgets tighten. The review gives no updated national count. It describes "GLP-1 deserts," areas where many people have obesity, wages are low and insurance rarely pays, so patients go without the drugs. People whose treatment is interrupted by these gaps end up with poorer blood sugar and weight results than people who keep steady access, the review says. It does not quantify that gap. For readers tracking GLP 1 Medicaid coverage, the January KFF count remains the most recent firm national figure in the material reviewed for this story. Any further change would come through decisions made state by state, since federal law leaves obesity coverage to each Medicaid program.
Medicare GLP 1 Bridge replaces the stalled BALANCE plan
Under the BALANCE Model, CMS bargains with drugmakers for lower GLP 1 prices, and state Medicaid programs and Medicare Part D plans that sign up get access to those terms. Participation is voluntary for drugmakers, states and plans. In a memo dated April 21, 2026, CMS put off the Part D launch planned for 2027 so it could gather more data and evaluate the plan further, the American Hospital Association reported. KFF said there was not enough interest among Part D plans to move forward. Medicare instead leans on the Medicare GLP 1 Bridge, a stand alone demonstration that started on July 1, 2026, and now lasts until December 31, 2027. It had been set to end in December 2026. The Bridge pays for certain obesity drugs apart from regular Part D coverage.
Eligible beneficiaries pay a fixed $50 copay for a one month supply under the Bridge, according to the Obesity Medicine Association. The Medicaid side of BALANCE went ahead. CMS took state applications until July 31, 2026, and each state could set its own start date in the window from May 1, 2026, to January 1, 2027, the AHA reported. A state that misses the January date can enter later only if CMS agrees. KFF said it is unclear how Medicare patients will hold on to coverage after the Bridge closes unless CMS acts further on Part D. The review did not name the states that have joined BALANCE, and no such list appeared in the sources checked for this story. That list will show how far the Medicaid price deals reach.
| Date | Program | What happened |
|---|---|---|
| April 21, 2026 | BALANCE Model, Part D | CMS memo delays the 2027 launch |
| May 1, 2026 | BALANCE Model, Medicaid | Earliest date states could begin |
| July 1, 2026 | Medicare GLP 1 Bridge | Coverage of select obesity drugs begins |
| July 31, 2026 | BALANCE Model, Medicaid | Deadline for state applications |
| January 1, 2027 | BALANCE Model, Medicaid | Last start date without CMS approval |
| December 31, 2027 | Medicare GLP 1 Bridge | Scheduled end, extended from December 2026 |
Cash prices and prescribing checks shape who stays on treatment
Brand name GLP 1 drugs still carry list prices of more than $1,000 a month, the review says. GLP 1 cash prices have fallen through manufacturer direct programs, which charge $349 a month for Wegovy, while the monthly Zepbound price runs from $299 to $449 with the dose, according to the review. It adds that the federal TrumpRx platform shows similar figures, and that many low income patients still cannot pay them. Citing a GoodRx survey, the review reports that cost predicts how patients feel about treatment more clearly than side effects or age. Millions of Americans with commercial insurance have no coverage for GLP 1 drugs approved for weight loss, it adds. A recent KFF employer survey found 18% of firms with 200 or more workers cover them for weight loss.
Prescribing raises separate questions. Citing a 2024 paper in Obesity Reviews, the review advises checking patients for disordered eating before treatment, watching for harmful appetite responses and prescribing with care in psychiatric patients. Because these drugs slow stomach emptying, they may change how some psychiatric medicines behave in the body, which could alter their effect or safety, the review says. Peptide Zone reported in October that a 45 member World Psychiatry panel backs eating disorder screening for every patient. Pharmacists often sort out insurance rules and prior authorization forms and help patients sign up for drugmaker and charity aid programs, according to the review. It adds that pharmacists can arrange clinic samples, teach and monitor patients and change insulin doses to keep glucose stable.
Conclusion
GLP 1 Medicaid coverage for obesity stood at 13 state programs in January 2026, according to KFF, and the review says more states have weighed cuts since. Medicare patients have the Bridge until the end of 2027, with no settled plan after that. The heart and kidney evidence the review describes applies to specific drugs and groups. The next markers are state budget decisions, any CMS action on Part D and the list of states in BALANCE. This report is for research and news, not medical advice.
